Chad M. Cohen's most recent trade in Grindr Inc - Ordinary Shares - Class A was a trade of 1,397 Common Stock done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Grindr Inc - Ordinary Shar... | Chad M. Cohen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 1,397 | 1,397 | - | 0 | Common Stock | |
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 30 Apr 2025 | 38,538 | 0 | - | - | Class A Common Stock | |
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 30 Apr 2025 | 8,158 | 38,538 | - | - | Class A Common Stock | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 30 Apr 2025 | 8,158 | 0 | - | - | Vacasa Holdings Units | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 30 Apr 2025 | 8,158 | 0 | - | - | Vacasa Employee Holdings LLC Interests | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 30 Apr 2025 | 8,158 | 8,158 | - | - | Vacasa Holdings Units | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 21 May 2024 | 20,134 | 30,380 | - | 0 | Class A Common Stock | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 23 May 2023 | 170,940 | 204,939 | - | 0 | Class A Common Stock | ||
| Vacasa Inc - Ordinary Shar... | Chad M. Cohen | Director | 24 May 2022 | 33,999 | 33,999 | - | 0 | Class A Common Stock | ||
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 22 Dec 2021 | 10,000 | 31,604 (0%) | 0% | 7.3 | 72,700 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 10,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 Dec 2021 | 10,000 | 21,604 (0%) | 0% | 30 | 300,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 09 Nov 2021 | 5,000 | 21,604 (0%) | 0% | 36.0 | 180,150 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 5,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 5,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.93 per share. | 09 Nov 2021 | 5,000 | 21,604 (0%) | 0% | 33.9 | 169,650 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Nov 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 09 Nov 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.51 per share. | 05 Oct 2021 | 5,000 | 21,604 (0%) | 0% | 32.5 | 162,550 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 5,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 5,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.30 per share. | 05 Oct 2021 | 5,000 | 21,604 (0%) | 0% | 32.3 | 161,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 05 Oct 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 05 Oct 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 07 Sep 2021 | 9,375 | 30,979 (0%) | 0% | 6.5 | 61,406 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 9,375 | 65,625 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.71 per share. | 07 Sep 2021 | 9,375 | 21,604 (0%) | 0% | 39.7 | 372,281 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 5,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.01 per share. | 07 Sep 2021 | 5,000 | 21,604 (0%) | 0% | 39.0 | 195,050 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 07 Sep 2021 | 5,000 | 26,604 (0%) | 0% | 7.3 | 36,350 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 10 Aug 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 10,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.48 per share. | 10 Aug 2021 | 8,738 | 22,866 (0%) | 0% | 33.5 | 292,548 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 10 Aug 2021 | 5,000 | 26,604 (0%) | 0% | 6.6 | 32,750 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 10 Aug 2021 | 5,000 | 21,604 (0%) | 0% | 35 | 175,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 5,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.47 per share. | 10 Aug 2021 | 1,262 | 21,604 (0%) | 0% | 34.5 | 43,501 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 06 Jul 2021 | 10,000 | 21,604 (0%) | 0% | 38.8 | 388,300 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 10,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 10,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 06 Jul 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 06 Jul 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.17 per share. | 06 Jul 2021 | 6,486 | 25,118 (0%) | 0% | 38.2 | 247,571 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 39.20 per share. | 06 Jul 2021 | 3,514 | 21,604 (0%) | 0% | 39.2 | 137,749 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 10,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 10,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.60 per share. | 08 Jun 2021 | 10,000 | 21,604 (0%) | 0% | 35.6 | 356,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 08 Jun 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 08 Jun 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.90 per share. | 08 Jun 2021 | 8,401 | 23,203 (0%) | 0% | 36.9 | 309,997 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.85 per share. | 08 Jun 2021 | 1,599 | 21,604 (0%) | 0% | 37.8 | 60,522 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 10,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.63 per share. | 11 May 2021 | 10,000 | 21,604 (0%) | 0% | 32.6 | 326,300 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 11 May 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.55 per share. | 11 May 2021 | 10,000 | 31,604 (0%) | 0% | 6.6 | 65,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 11 May 2021 | 7,031 | 21,604 (0%) | 0% | 31.8 | 223,867 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.81 per share. | 11 May 2021 | 2,969 | 28,635 (0%) | 0% | 30.8 | 91,475 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2021 | 10,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Apr 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 06 Apr 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.95 per share. | 06 Apr 2021 | 10,000 | 21,604 (0%) | 0% | 41.0 | 409,500 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2021 | 10,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.59 per share. | 06 Apr 2021 | 9,194 | 22,410 (0%) | 0% | 41.6 | 382,378 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.34 per share. | 06 Apr 2021 | 806 | 21,604 (0%) | 0% | 42.3 | 34,126 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 10 Mar 2021 | 10,000 | 31,604 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 10,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 42.54 per share. | 10 Mar 2021 | 10,000 | 21,604 (0%) | 0% | 42.5 | 425,400 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 10,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 09 Mar 2021 | 10,000 | 31,064 (0%) | 0% | 6.3 | 63,200 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 09 Mar 2021 | 7,110 | 23,954 (0%) | 0% | 40.0 | 284,542 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.79 per share. | 09 Mar 2021 | 2,890 | 21,064 (0%) | 0% | 40.8 | 117,883 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 51,511 | 51,511 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 20,604 | 21,604 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2021 | 50,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 28 Jan 2021 | 50,000 | 51,000 (0%) | 0% | 6.3 | 316,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 28 Jan 2021 | 50,000 | 51,000 (0%) | 0% | 6.3 | 316,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2021 | 50,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 55.77 per share. | 28 Jan 2021 | 38,112 | 12,888 (0%) | 0% | 55.8 | 2,125,506 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.00 per share. | 28 Jan 2021 | 23,698 | 19,523 (0%) | 0% | 56 | 1,327,088 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.00 per share. | 28 Jan 2021 | 18,523 | 1,000 (0%) | 0% | 57 | 1,055,811 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.68 per share. | 28 Jan 2021 | 9,704 | 3,184 (0%) | 0% | 56.7 | 550,023 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 55.04 per share. | 28 Jan 2021 | 7,779 | 43,221 (0%) | 0% | 55.0 | 428,156 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 57.70 per share. | 28 Jan 2021 | 2,184 | 1,000 (0%) | 0% | 57.7 | 126,017 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 25 Jan 2021 | 50,000 | 51,000 (0%) | 0% | 6.3 | 316,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 50,000 | 165,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 50,000 | 215,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 25 Jan 2021 | 50,000 | 51,000 (0%) | 0% | 6.3 | 316,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.69 per share. | 25 Jan 2021 | 20,953 | 19,436 (0%) | 0% | 65.7 | 1,376,403 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 64.54 per share. | 25 Jan 2021 | 20,785 | 6,920 (0%) | 0% | 64.5 | 1,341,464 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 67.03 per share. | 25 Jan 2021 | 17,436 | 2,000 (0%) | 0% | 67.0 | 1,168,735 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 63.65 per share. | 25 Jan 2021 | 12,977 | 27,705 (0%) | 0% | 63.6 | 825,986 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.08 per share. | 25 Jan 2021 | 10,611 | 40,389 (0%) | 0% | 65.1 | 690,564 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.71 per share. | 25 Jan 2021 | 10,318 | 40,682 (0%) | 0% | 62.7 | 647,042 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.47 per share. | 25 Jan 2021 | 5,920 | 1,000 (0%) | 0% | 65.5 | 387,582 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 67.68 per share. | 25 Jan 2021 | 1,000 | 1,000 (0%) | 0% | 67.7 | 67,680 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 20 Jan 2021 | 50,000 | 51,000 (0%) | 0% | 6.3 | 316,000 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2021 | 50,000 | 265,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 20 Jan 2021 | 33,938 | 6,012 (0%) | 0% | 67.3 | 2,285,724 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 66.82 per share. | 20 Jan 2021 | 11,050 | 39,950 (0%) | 0% | 66.8 | 738,361 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Cohen | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 68.33 per share. | 20 Jan 2021 | 5,012 | 1,000 (0%) | 0% | 68.3 | 342,470 | Common Stock |